Long-Term Care Updates
|
|
- Sabina Simmons
- 5 years ago
- Views:
Transcription
1 Long-Term Care Updates October/November 2015 By Daniel Kerner, PharmD A stroke occurs when blood flow to the brain is stopped or slowed, resulting in death or damage to brain cells. There are three main classifications of strokes: hemorrhagic stroke, ischemic stroke, and transient ischemic attack (TIA). A hemorrhagic stroke occurs when a blood vessel ruptures leading to bleeding in the brain. An ischemic stroke occurs when the blood supply to the brain is reduced or interrupted and the brain is deprived of vital oxygen and nutrients. Within a matter of minutes, brain cells are damaged and begin die. A TIA, also known as a mini-stroke, occurs when signs and symptoms of brain ischemia are present but clear within 24 hours. 1 In the U.S., around 795,000 people suffer from stroke each year, with 129,000 events resulting in death. Further, stroke is the leading cause of long-term disability in the United States. 2 Six months following a stroke, 26% of patients aged 65 years or older are dependent in their activities of daily living and 46% have cognitive deficits. 3 The following article will summarize and synthesize clinical practice guidelines for stroke prevention from the American Medical Directors Association (AMDA), American Heart Association/American Stroke Association (AHA/ASA), and American College of Chest Physicians (ACCP). While these guidelines provide significant evidence-based guidance on the prevention of stroke, patient-specific factors and clinician judgement should ultimately dictate an appropriate care plan. AMDA Clinical Practice Guideline In 2011, AMDA published guidelines for Stroke Management in the Long-Term Care Setting. The guidelines identify several modifiable risk factors for stroke (see Table 1). By identifying and treating these risk factors, the chance of a first-time or recurrent stroke is reduced. 1 AMDA cites one study suggesting that patients can lower their five-year cumulative risk of recurrent stroke by 80% by initiating antihypertensive medications, aspirin, a statin, exercise, and dietary adjustments. The 80% risk reduction translates to a number needed to treat of
2 Modifiable Risk Factors Atrial Fibrillation Carotid Artery Stenosis Cigarette Smoking Current Estrogen Use Diabetes Mellitus Hyperlipidemia Hypertension Inactivity Obesity Sleep Apnea Heavy Alcohol Use Table 1. AMDA Potentially Modifiable Risk Factors for Stroke five. This means that for every five patients that reach their dietary, exercise, and medication goals, one recurrent stroke is prevented. 3 Interventions recommended by AMDA to address modifiable risk factors of stroke follow: : For patients with hypertension, it is recommended that the dietary approaches to stop hypertension (DASH) diet is implemented. The DASH diet is a low sodium diet rich in fruits, vegetables, and low-fat dairy products which leads to reduced blood pressure, and thus, a lower risk of recurrent stroke. 1 Alcohol use can increase stroke risk by increasing risks of hypertension, atrial fibrillation, cardiomyopathy, and diabetes, and smoking has been associated with a greater than two-fold increase in risk for recurrent stroke in the elderly. 4 To reduce these risks, smoking cessation is recommended, and alcohol consumption should be restricted to two drinks daily for men and one drink daily for women. Patients that have had a past stroke should attempt to engage in 30 minutes of moderate-intensity physical exercise one to three times weekly. 1 While there are no controlled studies showing that physical activity reduces the incidence of recurrent stroke, physical activity has been shown to improve other modifiable risk factors such as obesity and hypertension. 5 : In patients with or without a history of hypertension for whom blood pressure lowering is appropriate, antihypertensive medications should be implemented after a stroke or TIA. Lowering blood pressure has been shown to reduce the risk of recurrent stroke. 6 The combination of an angiotensin-converting enzyme (ACE) inhibitor and a diuretic has shown the greatest benefit in reducing the risk of recurrent stroke compared to other antihypertensive agents. There is no clearly defined blood pressure goal for stroke prevention, but evidence of benefit from reducing blood pressure by as little as 10/5 mmhg has been seen. 1 : There are no data showing that targeting specific goals for glycosylated hemoglobin (HbA1c) or blood glucose decreases recurrent stroke risk. Glycemic goals should be based on existing diabetes guidelines in an attempt to improve overall patient health. Additionally, there are no data available showing that one class of oral antidiabetic agents is preferred over another for secondary stroke prevention. 1
3 : The AMDA guidelines cite a meta-analysis of statin therapy that showed reduction of low-density lipoprotein cholesterol (LDL-C) with statins reduces the incidence of stroke. 1 The AMDA guidelines agree with the current American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommending that patients 75 years or less with a prior stroke be started on a high-intensity statin, which produces a greater than 50% decrease in LDL-C. Patients greater than 75 years with a prior stroke should take a moderate-intensity statin, which produces a 30-50% decrease in LDL-C. 7 : For all patients with a prior TIA or thrombotic stroke not caused by a cardioembolism, antiplatelet therapy is recommended. For every 40 patients receiving antiplatelet therapy, one nonfatal stroke is prevented. Antiplatelet medications that can be used for recurrent stroke prevention include mg aspirin daily, aspirin 25 mg/extended-release dipyridamole 200 mg twice daily, or clopidogrel 75 mg daily. These agents have shown similar efficacy as antiplatelet monotherapy, and combination therapy has shown no added benefit for stroke prevention. 1 : To prevent stroke in patients with atrial fibrillation, anticoagulation is recommended. The AMDA guidelines maintain that anticoagulation with warfarin is the gold standard for stroke prevention in patients with atrial fibrillation. While warfarin is more effective than dabigatran for preventing stroke, it is associated with higher incidence of life-threatening hemorrhagic complications and requires more frequent monitoring. Therefore, dabigatran may be more appropriate for some patients. 1 Due to the date of approval, apixaban, edoxaban, and rivaroxaban are not addressed in the AMDA guidelines. : In addition to optimizing medication therapy as stated above, a carotid endarterectomy (CEA) is recommended in patients with greater than 70% stenosis. For patients that have 50% to 69% stenosis, CEA may be an option based on patient preference and suitability for surgery. Surgery is not recommended for patients with less than 50% stenosis. Carotid artery stenting may be a less invasive alternative to CEA. 1 discontinued in patients recovering from a stroke. 1 : Estrogen with or without a progestin can increase the risk of stroke. Estrogen therapy should be AHA/ASA Guidelines The AHA and ASA published updated guidelines for the prevention of stroke in patients with stroke and TIA in The purpose of these guidelines was to provide comprehensive, evidence-based recommendations for the prevention of future stroke in those that have previously experienced an ischemic stroke or TIA. 4 These guidelines were an update of the 2011 AHA/ASA statement on secondary stroke prevention. 5 The AHA/ASA guidelines differentiate between non-modifiable and modifiable risk factors for stroke. Non-modifiable risk factors include older age, low birth weight, race/ethnicity, and genetic factors that cannot be controlled in the prevention of stroke. AHA/ASA does not offer recommendations to counteract these non-modifiable risk factors. However, the guidelines provide several recommendations for modifiable risk factors. Recommendations for intervention for vascular obstruction and antithrombotic/antiplatelet therapy are also provided. Table 2 summarizes the recommendations made by the AHA/ASA. As some of these recommendations are similar to the AMDA guidelines, the table will only include recommendations that differ from or are in addition to the recommendations stated above.
4 Table 2. AHA/ASA Recommendations for Prevention of Stroke in Patients with Stroke and TIA 4 Section Diet and Nutrition Hypertension Atrial Fibrillation Sleep Apnea Intracranial Atherosclerosis Hypercoagulation Sickle Cell Disease Prosthetic Heart Valve Recommendations Single vitamin or multivitamin supplementation is not recommended as this has not shown a proven benefit in secondary stroke prevention. To lower the stroke risk associated with elevated blood pressure, patients with a history of stroke or TIA should reducer sodium intake to less than 2.4 g/day. Greater blood pressure reduction may be seen with sodium intake reduction to <1.5 g/day. A Mediterranean diet, which consists of fruits, vegetables, whole grains, low-fat dairy products, poultry, fish, legumes, nuts, and olive oil has also shown to decrease blood pressure. For patients with stroke or TIA, not previously treated for hypertension, and with a blood pressure 140/90 mmhg, antihypertensive therapy should be initiated within the first few days post-stroke to prevent recurrent stroke. For patients that have had a stroke or TIA and have been previously treated for hypertension, blood pressure lowering therapy should be resumed after the first several days post-stroke. To prevent recurrent stroke in atrial fibrillation patients that cannot take oral anticoagulants, aspirin monotherapy is recommended. Dual therapy of clopidogrel and aspirin has also shown benefit in secondary stroke prevention. Oral anticoagulation should be initiated within 14 days of the onset of neurological symptoms for most patients following a stroke or TIA. This may be delayed in instances of hemorrhagic risk, such as a large infarct, uncontrolled hypertension, or hemorrhage tendency. A sleep study may be warranted in patients following a stroke or TIA due to the high prevalence of sleep apnea in this population. Treatment with continuous positive airway pressure (CPAP) has shown to reduce recurrent stroke risk in patients with sleep apnea following a stroke or TIA. Ninety day treatment with clopidogrel 75 mg/day plus aspirin may be warranted to reduce recurrent stroke risk in patients suffering from stroke or TIA within 30 days of severe stenosis (70%-99%) of a major intracranial artery. Systolic blood pressure should be maintained at <140 mmhg and a high-intensity statin therapy should be initiated for patients with a stroke or TIA due to 50% to 99% stenosis of a major intracranial artery. For patients with a stroke or TIA due to moderate stenosis (50%-69%) of a major intracranial artery, the periprocedural risk of angioplasty or stenting outweighs the benefit of decreasing the low rate of recurrent stroke and is not recommended. If anticoagulation therapy is not administered in patients with abnormal findings on coagulation testing, antiplatelet therapy is recommended to reduce the risk of recurrent stroke. Reducing hemoglobin S to <30% of total hemoglobin via chronic blood transfusions has shown to significantly decrease the rate or recurrent stroke in patients with sickle cell disease and prior stroke or TIA. For patients with a history of stroke or TIA prior to the insertion of a mechanical aortic valve, warfarin therapy is recommended with an INR target of 2.5 (range, ). For patients with a history of stroke or TIA prior to the insertion of a mechanical mitral valve, warfarin therapy is recommended with an INR target of 3.0 (range, ). For low bleeding risk patients with a history of stroke or TIA prior to the insertion of a mechanical aortic or mitral valve, the addition of aspirin mg/day to warfarin therapy is recommended. For patients with a history of stroke or TIA prior to the insertion of a bioprosthetic aortic or mitral valve that are not indicated for anticoagulation therapy beyond 3 to 6 months from the valve placement, long-term therapy with aspirin mg/day is preferred over long-term anticoagulation due to decreased risk of thromboembolism in these patients.
5 ACCP Guidelines The ACCP published updated guidelines regarding antithrombotic and thrombolytic therapy for ischemic stroke in The purpose of these guidelines was to provide comprehensive, evidence-based recommendations for the treatment of acute stroke and prevention of recurrent stroke. 8 ACCP s recommendations for secondary stroke prevention are included in table 3 below. Table 3. ACCP Antithrombotic Recommendations for Secondary Stroke Prevention. 8 Population Recommendations History of Noncardioembolic Stroke or TIA History of Ischemic Stroke or TIA and Atrial Fibrillation (including Paroxysmal Atrial Fibrillation) History of Symptomatic Primary Intracerebral Hemorrhage Long-term treatment with aspirin mg daily, clopidogrel 75 mg daily, aspirin/extended-release dipyridamole 25 mg/200 mg, or cilostazol 100 mg twice daily is recommended over no antiplatelet therapy, oral anticoagulants, or clopidogrel plus aspirin. Clopidogrel or aspirin/extended-release dipyridamole is recommended over aspirin or cilostazol. Oral anticoagulation is recommended over no antithrombotic therapy, aspirin, or aspirin plus clopidogrel. Oral anticoagulation with dabigatran 150 mg twice daily is recommended over dose-adjusted warfarin. In patients who are contraindicated to or cannot tolerate oral anticoagulants, aspirin plus clopidogrel is recommended over aspirin alone. Long-term use of antithrombotic therapy is not recommended. Summary A stroke has the potential to be very debilitating and can lead to substantial cognitive deficits. Several modifiable risk factors that can be corrected to lower the risk of a stroke recurrence exist. Implementing lifestyle modifications such as the DASH diet, smoking cessation, decreased alcohol consumption, and physical activity has shown positive effects on stroke prevention. In addition, pharmacological treatment to manage blood pressure, cholesterol, diabetes, and atrial fibrillation further reduces the risk of recurrent stroke. By managing all of the modifiable risk factors, patient outcomes and overall health can be improved.
6 1. American Medical Directors Association. Stroke Management in the Long-Term Care Setting Clinical Practice Guideline. Columbia, MD: AMDA American Heart Association and American Stroke Association. Heart Disease and Stroke States At-A-Glance. Dallas, TX: AHA Meschia JF, Bushnell C, Boden-Albala B, et al. Guidelines for the primary prevention of stroke: A statement for healthcare professionals from the American Heart Association/ American Stroke Association. 2014;45(12): Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. 2014;45(7): Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. 2011;42(1): Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: A systematic review. 2003;34(11): Stone NJ, Robinson J, Lichtenstein AH, et al ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014;129(25 Suppl 2):S Lansberg MG, O Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic therapy and prevention of thrombosis, 9 th ed: American College of Chest Physicians evidence-based clinical practice guidelines. 2012;141(2 Suppl):e601S-36S.
Do Not Cite. Draft for Work Group Review.
Defect Free Acute Inpatient Ischemic Stroke Measure Bundle Measure Description Percentage of patients aged 18 years and older with a diagnosis of ischemic stroke OR transient ischemic attack who were admitted
More informationStroke: Prevention is the Best Medicine
Stroke: Prevention is the Best Medicine Donna Lindsay, MN, RN, CNS-BC, SCRN Neuroscience Clinical Nurse Specialist/ Stroke Program Coordinator Hennepin Stroke Center Stroke Statistics Approximately 795,000
More informationStroke 101. Maine Cardiovascular Health Summit. Eileen Hawkins, RN, MSN, CNRN Pen Bay Stroke Program Coordinator November 7, 2013
Stroke 101 Maine Cardiovascular Health Summit Eileen Hawkins, RN, MSN, CNRN Pen Bay Stroke Program Coordinator November 7, 2013 Stroke Statistics Definition of stroke Risk factors Warning signs Treatment
More informationCoronary Artery Disease (CAD) Clinician Guide SEPTEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Coronary Artery Disease (CAD) Clinician Guide SEPTEMBER 2017 Introduction This Clinician Guide is based on the 2017 KP National Coronary Artery Disease
More informationCoronary Artery Disease Clinical Practice Guidelines
Coronary Artery Disease Clinical Practice Guidelines Guidelines are systematically developed statements to assist patients and providers in choosing appropriate healthcare for specific clinical conditions.
More informationGuiding Secondary Stroke Prevention through Evaluation of Ischemic Stroke Etiology
Guiding Secondary Stroke Prevention through Evaluation of Ischemic Stroke Etiology Ann M. Leonhardt Caprio, MS, RN, ANP-BC Program Coordinator Comprehensive Stroke Center, Strong Memorial Hospital Clinical
More informationEach year in the United States, > adults experience. AHA/ASA Guideline
AHA/ASA Guideline Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack A Guideline for Healthcare Professionals From the American Heart Association/American Stroke
More informationNeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More informationSection Editor Scott E Kasner, MD
1 of 6 9/29/2013 6:55 PM Official reprint from UpToDate www.uptodate.com 2013 UpToDate The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis,
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationSIGN 149 Risk estimation and the prevention of cardiovascular disease. Quick Reference Guide July Evidence
SIGN 149 Risk estimation and the prevention of cardiovascular disease Quick Reference Guide July 2017 Evidence ESTIMATING CARDIOVASCULAR RISK R Individuals with the following risk factors should be considered
More informationBranko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center
Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center THE END! CHANGABLE Blood pressure Diabetes Mellitus Hyperlipidemia Atrial fibrillation Nicotine Drug abuse Life style NOT CHANGABLE
More information2013 Hypertension Measure Group Patient Visit Form
Please complete the form below for 20 or more unique patients meeting patient sample criteria for the measure group for the current reporting year. A majority (11 or more) patients must be Medicare Part
More informationPrimary Prevention of Stroke
Primary Prevention of Stroke Dr Chris Ellis Cardiologist Green Lane CVS Service, Auckland City Hospital & Auckland Heart Group, Mercy Hospital, Auckland 67 Pages Long, 735 References 29 Sub-Headings for
More informationPharmacy STROKE. Anne Kinnear Lead Pharmacist NHS Lothian. Educational Solutions for Workforce Development
STROKE Anne Kinnear Lead Pharmacist NHS Lothian Aim To update pharmacists on Stroke: the disease and its management and explore ways to implement pharmaceutical care for this patient group as part of normal
More informationStroke Awareness. Presented by Jai Cho, MD Director of Stroke Unit Department of Neurology Kaiser Permanente, Santa Clara Medical Center.
Stroke Awareness Presented by Jai Cho, MD Director of Stroke Unit Department of Neurology Kaiser Permanente, Santa Clara Medical Center May 5, 2009 FACTS: Strokes in the U.S. Third leading cause of death
More informationSteps Against Recurrent Stroke (STARS)
Steps Against Recurrent Stroke (STARS) Take steps against recurrent stroke by making the necessary changes in your life. Your Guide to Ischemic Stroke What happened to me? You had a stroke. The stroke
More informationPrimary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group
Primary and Secondary Prevention of Cardiovascular Disease Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group AHA Diet and Lifestyle Recommendations Balance calorie intake and physical activity to
More informationSteps Against Recurrent Stroke (STARS)
Steps Against Recurrent Stroke (STARS) Take steps against recurrent stroke by making the necessary changes in your life Your Guide to Ischemic What Happened to Me? You had a stroke. The stroke you had
More informationMike Previti, MD UW Valley Medical Center, Stroke Program Medical Director UW, Dept of Neurology, Clinical Instructor
Mike Previti, MD UW Valley Medical Center, Stroke Program Medical Director UW, Dept of Neurology, Clinical Instructor What is TIA? TIA vs CVA, does it matter? Who needs the hospital? What is the ABCD 2
More information5/2/2016. Outpatient Stroke Management Sheila Smith MD May 5, 2016
Outpatient Stroke Management Sheila Smith MD May 5, 2016 1 Management of Outpatient Stroke Objectives Review blood pressure management post stroke Review antithrombotic therapy Review statin therapy Discuss
More informationDr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre
Dr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre Objectives To learn what s new in stroke care 2010-11 1) Acute stroke management Carotid artery stenting versus surgery for symptomatic
More informationEvidenceNOW SW Learning Collaborative. Kyle Knierim, MD January 2017
EvidenceNOW SW Learning Collaborative Kyle Knierim, MD January 2017 What is cardiovascular disease? Why are we even talking about cardiovascular disease? What can we do to prevent and treat cardiovascular
More informationCEREBRO VASCULAR ACCIDENTS
CEREBRO VASCULAR S MICHAEL OPONG-KUSI, DO MBA MORTON CLINIC, TULSA, OK, USA 8/9/2012 1 Cerebrovascular Accident Third Leading cause of deaths (USA) 750,000 strokes in USA per year. 150,000 deaths in USA
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More informationUnderstanding Risk Factors for Stroke
MINTO PREVENTION & REHABILITATION CENTRE CENTRE DE PREVENTION ET DE READAPTATION MINTO Understanding Risk Factors for Stroke About This Kit Risk factors have been identified that can predict who is most
More informationStroke Prevention. For more information about stroke, call University Hospital s Heart Line at 706/ or toll free at 866/
Stroke Prevention Drug Use: The use of illicit drugs, including cocaine and crack cocaine, can cause stroke. Cocaine may act on other risk factors, such as hypertension, heart disease and vascular disease,
More informationSteps Against Recurrent Stroke (STARS)
Steps Against Recurrent Stroke (STARS) Take steps against recurrent stroke by making the necessary changes in your life. Your Guide to Ischemic What happened to me? You had a stroke. The stroke you had
More informationIntervention Recommendations with Class of Recommendation and Level of Evidence
Intervention Recommendations with Class of Recommendation and Level of Evidence RISK: BLOOD PRESSURE CONTROL: LIPID Goal: to identify people who will benefit from risk reduction strategies Goal:
More informationPatients who experience a stroke or transient ischemic
REPORTS Therapeutic Interventions for Prevention of Recurrent Ischemic Stroke Howard S. Kirshner, MD Abstract Patients who suffer ischemic stroke or transient ischemic attack (TIA) are at increased risk
More informationClinical Practice Guideline
Clinical Practice Guideline Secondary Prevention for Patients with Coronary and Other Vascular Disease Since the 2001 update of the American Heart Association (AHA)/American College of Cardiology (ACC)
More informationSubject Expert. Michelle Whaley MSN, CNS, CCNS, ANVP-BC Swedish Medical Center Englewood, CO
Stroke 101 Subject Expert Michelle Whaley MSN, CNS, CCNS, ANVP-BC Swedish Medical Center Englewood, CO 2 Objectives Types of strokes Stroke warning signs Stroke risk factors Medical test performed following
More informationManagement and Investigation of Ischemic Stroke By Etiology
Management and Investigation of Ischemic Stroke By Etiology Andrew M. Demchuk MD FRCPC Director, Calgary Stroke Program Deputy Dept Head, Clinical Neurosciences Heart and Stroke Foundation Chair in Stroke
More informationSecondary Stroke Prevention: A Precautionary Tale
Secondary Stroke Prevention: A Precautionary Tale Kirsten George-Phillips, BSP Clinical Practice Leader, AHS Clinical Pharmacist, AHS Owen Stroke Prevention Clinic Learning Objectives! Examine literature
More informationCardiovascular Diseases and Diabetes
Cardiovascular Diseases and Diabetes LEARNING OBJECTIVES Ø Identify the components of the cardiovascular system and the various types of cardiovascular disease Ø Discuss ways of promoting cardiovascular
More informationClinical Practice Guideline for Anticoagulation Management
Clinical Practice Guideline for Anticoagulation Management This guideline is to inform practitioners of the Standard of Care for providing safe and effective anticoagulation management for ambulatory patients.
More informationOUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.
OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To review the use of antiplatelet agents and oral
More informationStrokes , The Patient Education Institute, Inc. hp Last reviewed: 11/11/2017 1
Strokes Introduction A stroke or a brain attack is a very serious condition that can result in death and significant disability. This disease is ranked as the third leading cause of death in the United
More informationStroke secondary prevention. Gill Cluckie Stroke Nurse Consultant St. George s Hospital
Stroke secondary prevention Gill Cluckie Stroke Nurse Consultant St. George s Hospital Stroke recurrence The risk of recurrent stroke is greatest after first stroke 2 3% of survivors of a first stroke
More informationAntithrombotic therapy in patients with transient ischemic attack / stroke (acute phase <48h)
Antithrombotic therapy in patients with transient ischemic attack / stroke (acute phase
More informationDental Management Considerations for Patients on Antithrombotic Therapy
Dental Management Considerations for Patients on Antithrombotic Therapy Warfarin and Antiplatelet Joel J. Napeñas DDS FDSRCS(Ed) Program Director General Practice Residency Program Department of Oral Medicine
More informationFrom the desk of the: THE VIRTUAL NEPHROLOGIST
Hypertension, also referred to as high blood pressure or HTN, is a medical condition in which the blood pressure is chronically elevated. It is a very common illness. One out of three American adults has
More informationAlan Barber. Professor of Clinical Neurology University of Auckland
Alan Barber Professor of Clinical Neurology University of Auckland Presented with L numbness & slurred speech 2 episodes; 10 mins & 2 hrs Hypertension Type II DM Examination pulse 80/min reg, BP 160/95
More information2018 Early Management of Acute Ischemic Stroke Guidelines Update
2018 Early Management of Acute Ischemic Stroke Guidelines Update Brandi Bowman, PhC, Pharm.D. April 17, 2018 Pharmacist Objectives Describe the recommendations for emergency medical services and hospital
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised
Name: generic (trade) Dabigatran etexilate (Pradaxa ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised Direct thrombin inhibitor
More informationSubclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study
Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study Meagan Sullivan, PharmD PGY2 Cardiology Pharmacy Resident University of Chicago Medicine
More informationSession 21: Heart Health
Session 21: Heart Health Heart disease and stroke are the leading causes of death in the world for both men and women. People with pre-diabetes, diabetes, and/or the metabolic syndrome are at higher risk
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Warfarin and the risk of major bleeding events in patients with atrial fibrillation: a population-based study Laurent Azoulay PhD 1,2, Sophie Dell Aniello MSc 1, Teresa
More informationQuestion 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG:
Atrial Fibrillation in Your Area Question 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG: a) What was the prevalence of atrial fibrillation (AF)? 6636 (as of 22/10/2015) 2.1%
More informationSTAYING HEART HEALTHY PAVAN PATEL, MD CONSULTANT CARDIOLOGIST FLORIDA HEART GROUP
STAYING HEART HEALTHY PAVAN PATEL, MD CONSULTANT CARDIOLOGIST FLORIDA HEART GROUP What is Heart Disease Cardiovascular Disease (CVD): Heart or Blood vessels are not working properly. Most common reason
More informationAlan Barber. Professor of Clinical Neurology University of Auckland
Alan Barber Professor of Clinical Neurology University of Auckland Presented with Non-fluent dysphasia R facial weakness Background Ischaemic heart disease Hypertension Hyperlipidemia L MCA branch
More informationShawke A. Soueidan, MD. Riverside Neurology & Sleep Specialists
Shawke A. Soueidan, MD Riverside Neurology & Sleep Specialists 757-221-0110 Epidemiology of stroke 2018 Affects nearly 800,000 people in the US annually Approximately 600000 first-ever strokes and 185000
More informationApixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis
Apixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis Caitlin Reedholm, PharmD PGY1 Pharmacy Resident St. David s South Austin Medical Center November 2, 2018 Abbreviations
More informationAtrial Fibrillation Implementation challenges. Lesley Edgar Ross Maconachie
Atrial Fibrillation Implementation challenges Lesley Edgar Ross Maconachie Atrial Fibrillation Most common heart rhythm disturbance Rapid and irregular electrical signals Reduced efficiency of blood flow
More informationscience is why 2014 American Heart Association, Inc. All rights reserved.
Guidelines for the Primary Prevention of Stroke A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association The American Academy of Neurology affirms the value
More informationCONCISE GUIDE National Clinical Guidelines for Stroke 2nd Edition
CONCISE GUIDE 2004 National for Stroke 2nd Edition This concise guide summarises the recommendations, graded according to the evidence, from the National 2nd edition. As critical aspects of care are not
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY
More informationAnti-thromboticthrombotic drugs
Atrial Fibrillation 2011: Anticoagulation strategies and clinical outcomes Panos E. Vardas President Elect of the ESC, Prof. of Cardiology, University Hospital of Crete Clinical outcomes affected by AF
More informationPrimary Care practice clinics within the Edmonton Southside Primary Care Network.
INR Monitoring and Warfarin Dose Adjustment Last Review: November 2016 Intervention(s) and/or Procedure: Registered Nurses (RNs) adjust warfarin dosage according to individual patient International Normalized
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationDrug Class Monograph
Drug Class Monograph Class: Oral Anticoagulants Drug: Coumadin (warfarin), Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), arelto (rivaroxaban) Formulary Medications: Eliquis (apixaban),
More informationJoshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine
Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Antithrombotics Antiplatelets Aspirin Ticlopidine Prasugrel Dipyridamole
More informationE X P L A I N I N G STROKE
EXPLAINING STROKE Introduction Explaining Stroke is a practical step-by-step booklet that explains how a stroke happens, different types of stroke and how to prevent a stroke. Many people think a stroke
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Myocardial infarction: secondary prevention in primary and secondary care for patients following a myocardial infarction 1.1
More informationCardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003
Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationDiagnosis: Allergies with reaction type:
Patient Name: Diagnosis: Allergies with reaction type: ICU Stroke-Ischemic S/P tpa Version 2 5/29/14 This order set is designed to be used with an admission set or for a patient already admitted Nursing
More informationNanik Hatsakorzian Pharm.D/MPH
Pharm.D/MPH 2014 1 Therapeutics FDA indication & Dosing Clinical Pearls Anticoagulants Heparin Antiphospholipid antibody syndrome Cerebral thromboembolism Prosthetic heart valve Acute coronary syndrome
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Xian Y, Liang L, et al. Association of intracerebral hemorrhage among patients taking non vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital
More informationFølgende dias er fremlagt ved DCS / DTS Fællesmøde 13. januar 2011 og alle rettigheder tilhører foredragsholderen. Gengivelse må kun foretages ved
. Følgende dias er fremlagt ved DCS / DTS Fællesmøde 13. januar 2011 og alle rettigheder tilhører foredragsholderen. Gengivelse må kun foretages ved tilladelse Antithrombotic therapy in Atrial Fibrillation
More informationHow good is current best medical therapy (BMT) for stroke prevention in patients with asymptomatic carotid stenosis?
How good is current best medical therapy (BMT) for stroke prevention in patients with asymptomatic carotid stenosis? Dorothee Saur Department of Neurology University of Leipzig Disclosure for Dorothee
More informationWhat is hypertension?
HYPERTENSION What is hypertension? Abnormally elevated arterial blood pressure that is usually indicated by an adult systolic blood pressure of 140 mm Hg or greater or a diastolic blood pressure of 90
More informationVariables in Riksstroke - TIA
Variables in Riksstroke - TIA The TIA registration started 2010 for patients treated in hospital and 2015 it was 67 of 72 hospitals are registrating TIA On the www.riksstroke.org/forms/ you find the Riksstroke
More information1. What is the preferred method of anticoagulating a high-risk cardiac patient on chronic warfarin therapy. anticoagulation can be continued,
Experts Answering Your Questions Anticoagulating a high-risk cardiac patient 1. What is the preferred method of anticoagulating a high-risk cardiac patient on chronic warfarin therapy for minor surgical
More informationLecture 8 Cardiovascular Health Lecture 8 1. Introduction 2. Cardiovascular Health 3. Stroke 4. Contributing Factors
Lecture 8 Cardiovascular Health 1 Lecture 8 1. Introduction 2. Cardiovascular Health 3. Stroke 4. Contributing Factors 1 Human Health: What s Killing Us? Health in America Health is the U.S Average life
More informationGuideline scope Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (update)
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Guideline scope Stroke and transient ischaemic attack in over s: diagnosis and initial management (update) 0 0 This will update the NICE on stroke and
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process
Quality ID #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Management of Chronic
More informationA Patient with Chest Pain and Atrial Fibrillation
A Patient with Chest Pain and Atrial Fibrillation Kurt Huber, Vienna, Austria Declaration of Interest Lecturing & Consulting Activities: AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More information2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary
2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease Becky McKibben, MPH; Seth
More informationSlide 1. Slide 2 Conflict of Interest Disclosure. Slide 3 Stroke Facts. The Treatment of Intracranial Stenosis. Disclosure
Slide 1 The Treatment of Intracranial Stenosis Helmi Lutsep, MD Vice Chair and Dixon Term Professor, Department of Neurology, Oregon Health & Science University Chief of Neurology, VA Portland Health Care
More informationDirect Oral Anticoagulant Use in Valvular Atrial Fibrillation
Direct Oral Anticoagulant Use in Valvular Atrial Fibrillation September 14, 2018 Nina Maguire, PharmD PGY1 Pharmacy Resident Seton Healthcare Family Christina.maguire@ascension.org ASCENSION TEXAS Direct
More informationUpdate on Oral Anticoagulation for Mechanical Heart Valves
Update on Oral Anticoagulation for Mechanical Heart Valves Douglas C. Anderson, Pharm.D., D.Ph. Professor and Chair Dept. of Pharmacy Practice Cedarville University School of Pharmacy OHIO SOCIETY OF HEALTH-SYSTEM
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationStroke Support Group
Mercy Walworth Hospital and Medical Center Stroke Support Group Angie Schnobel, MS, CCC-SLP Hannah Herland, MOTR/L Karen Graham, LPTA MercyWalworthStrokeSupport.org Meeting second Tuesday of the month
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationManuel Castella MD PhD Hospital Clínic, University of
Manuel Castella MD PhD Hospital Clínic, University of Barcelona mcaste@clinic.ub.es @mcastellamd www.escardio.org/guidelines European Heart Journal - doi:10.1093/eurheartj/ehw210 Providing integrated care
More informationCanadian Best Practice Recommendations for Stroke Care. (Updated 2008) Section # 3 Section # 3 Hyperacute Stroke Management
Canadian Best Practice Recommendations for Stroke Care (Updated 2008) Section # 3 Section # 3 Hyperacute Stroke Management Reorganization of Recommendations 2008 2006 RECOMMENDATIONS: 2008 RECOMMENDATIONS:
More informationAPPENDIX A NORTH AMERICAN SYMPTOMATIC CAROTID ENDARTERECTOMY TRIAL
APPENDIX A Primary Findings From Selected Recent National Institute of Neurological Disorders and Stroke-Sponsored Clinical Trials That Have shaped Modern Stroke Prevention Philip B. Gorelick 178 NORTH
More informationGWTG Post-Discharge Follow-up Form
Bold font = Required field Patient ID: Date of Hospital Admission: / / mm / dd / yyyy Date Follow-up Completed: / / mm / dd / yyyy PATIENT LOGISTICS Method used for Patient follow-up: Chart Review Health
More informationAtrial Fibrillation and Heart Failure: A Cause or a Consequence
Atrial Fibrillation and Heart Failure: A Cause or a Consequence Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania November
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationFor instance, it can harden the arteries, decreasing the flow of blood and oxygen to the heart. This reduced flow can cause
High Blood Pressure Blood pressure is the force of blood against your artery walls as it circulates through your body. Blood pressure normally rises and falls throughout the day, but it can cause health
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationAtrial Fibrillation. 2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018
2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018, MSc, FACP, SFHM Division of Hospital Medicine Henry Ford Hospital Detroit, USA Clinical Associate Professor of Medicine Wayne
More informationEpidemiology and Prevention of Stroke
Copyright Information Copyright protected material has been deleted from this presentation. References to the deleted material are provided for each slide. Epidemiology and Prevention of Stroke Larry B.
More informationCarotid Artery Disease and What s Pertinent JOSEPH A PAULISIN DO
Carotid Artery Disease and What s Pertinent JOSEPH A PAULISIN DO Goal of treatment of carotid disease Identify those at risk of developing symptoms Prevent patients at risk from developing symptoms Prevent
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationHeart disease in Women
Heart disease in Women Extent and risk assessment Charles McCreery MB FACC St Vincent's Hospital Dublin St Columcille s Hospital Dublin Natural Progression of Atherosclerosis Heart disease risk differs
More information